Literature DB >> 6134533

Alpha-adrenergic drugs. Pharmacological tools for the study of the central vasomotor control.

P Bousquet, J Schwartz.   

Abstract

Mesh:

Substances:

Year:  1983        PMID: 6134533     DOI: 10.1016/0006-2952(83)90466-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  7 in total

1.  Clinical study of epidural analgesia with clonidine and sumatriptan in posthysterectomy.

Authors:  Z Liu; Y Tian; C Zhang; S Jin
Journal:  J Tongji Med Univ       Date:  1997

2.  Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine.

Authors:  D S Charney; A Breier; P I Jatlow; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Protective action of clonidine against the arrhythmogenic and lethal effects of ouabain in guinea-pigs.

Authors:  G P Thomas; P M Stephen
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

4.  Effects of trazodone treatment on alpha-2 adrenoceptor function in depressed patients.

Authors:  L H Price; D S Charney; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Effects of imidazole compounds on catecholamine release in adrenal chromaffin cells.

Authors:  M Ohara-Imaizumi; K Kumakura
Journal:  Cell Mol Neurobiol       Date:  1992-06       Impact factor: 5.046

6.  A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.

Authors:  P Ernsberger; M A Haxhiu; L M Graff; L A Collins; I Dreshaj; D L Grove; M E Graves; S G Schäfer; M O Christen
Journal:  Cardiovasc Drugs Ther       Date:  1994-03       Impact factor: 3.727

Review 7.  Historic aspects in the identification of the I1 receptor and the pharmacology of imidazolines.

Authors:  P Dominiak
Journal:  Cardiovasc Drugs Ther       Date:  1994-03       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.